Compare AbCellera Biologics Inc (ABCL) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Beyond Meat Inc — how do they compare? AbCellera Biologics Inc trades at $8.98 (market cap $2.85B), while Beyond Meat Inc trades at $0.42 (market cap $268.23M). The key difference: AbCellera Biologics Inc is far larger — about 10.6× Beyond Meat Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BYND | |
|---|---|---|
Market Cap | $2.85B | $268.23M |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $3.62 |
52-Week Low | $2.78 | $0.42 |
Enterprise Value | $2.45B | $508.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
BYND trades at $0.5377, up 1.93% today, but remains in a deep bearish technical trend with weak sentiment. The company reported a surprising net income of $178M in 2025 after years of losses, though revenue continues to decline. Recent Q2 2026 earnings showed a smaller loss than expected, with management focusing on international expansion and new product launches like Beyond Steak Filet to drive a turnaround.
The outlook remains challenging with declining revenue, negative operating cash flow, and heavy reliance on financing. Analyst consensus is overwhelmingly bearish with 57% sell ratings. Key risks include execution of the turnaround strategy, intense competition, and persistent cash burn. The stock presents high risk with potential reward contingent on successful business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
